

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

SANOFI-AVENTIS

2. Address:

801 PENNSYLVANIA AVENUE, NW SUITE 725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

City: Bridgewater State/Zip(or Country): NJ 08807

4. Contact Name: JONATHAN B. SPEAR

Telephone: 2026280500

E-mail (optional): nwerren@stateandfed.com

Senate ID #: 56838-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 3,560,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S1145 and HR1908 "Patent Reform Act of 2007" (all provisions)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: EVANS, EDDIE D.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

The protection of intellectual property rights helps encourage ongoing research and development of innovative pharmaceutical and biotechnology treatments and advances the quality of healthcare for people. To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the foreign parent company will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: DEF (one per page)

16. Specific lobbying issues:

HR1585 "National Defense Authorization Act for FY2008" (issues and provisions related to reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System); issues related to TRICARE and the Task Force on the Future of Military Healthcare

17. House(s) of Congress and Federal agencies contacted:

Defense, Dept of (DDD)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HODGE, RICHARD
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Reimbursement and health care quality issues related to Military healthcare could negatively impact the sanofi-aventis US operation which could result in less than optimal pharmaceutical care for US military personnel and their families. To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the parent company that is a foreign company, will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: FIN (one per page)

16. Specific lobbying issues:

Issues related to the reform of the CFIUS review process, including HR556 "National Security Foreign Investment Reform and Strengthened Transparency" and S1610 "Foreign Investment and National Security Act of 2007"

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: TAYLOR, ANN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the parent company that is a foreign company, will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Issues related to follow on biologics, drug safety, importation/reimportation of prescription drugs, drug advertising, and the Citizen's Petition process, including such provisions in S1082 "The Food and Drug Revitalization Act of 2007" and HR2900 "The Food and Drug Administration Amendments Act of 2007"

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CLARK, TIM

Covered Official Position (if applicable): N/A

Name: COOK, JUDY

Covered Official Position (if applicable): N/A

Name: EVANS, EDDIE D.

Covered Official Position (if applicable): N/A

Name: GREISSING, ED

Covered Official Position (if applicable): N/A

Name: HODGE, RICHARD

Covered Official Position (if applicable): N/A

Name: SPEAR, JONATHAN

Covered Official Position (if applicable): N/A

Name: SULTAN, SAIRA

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the foreign parent company will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

coding and reimbursement or coverage issues for Medicare Part B products and Medicare Part D services, preventative health screenings and assessments, and obesity drugs; issues related to DVT prevention and awareness, including draft legislation "Deep Vein Thrombosis Prevention Act of 2007"; issues related to osteoporosis prevention and awareness. HR4 and S3 "Medicare Prescription Drug Price Negotiation Act Of 2007" (All Provisions); issues and provisions related to the closure of the Medicare Part D donut hole and other improvements for beneficiaries of the Medicare program, and the Medicaid drug rebate, including such provisions in HR3162 "The Children's Health and Medicare Protection Act of 2007" and S1607 "The Children's Health Insurance Program Reauthorization Act of 2007";

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CLARK, TIM
Covered Official Position (if applicable): N/A
Name: COIN, MARK
Covered Official Position (if applicable): N/A
Name: COOK, JUDY
Covered Official Position (if applicable): N/A
Name: EVANS, EDDIE D.
Covered Official Position (if applicable): N/A
Name: GREISSING, ED
Covered Official Position (if applicable): N/A
Name: HODGE, RICHARD
Covered Official Position (if applicable): N/A
Name: SPEAR, JONATHAN
Covered Official Position (if applicable): N/A
Name: SULTAN, SAIRA
Covered Official Position (if applicable): N/A
Name: TAYLOR, ANN
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the foreign parent company will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

HR2138 "Investment in America Act of 2007" (all provisions)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COOK, JUDY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the foreign parent company will likewise be impacted.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Issues related to Thailand issuing compulsory license of innovative pharmaceuticals.

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: TAYLOR, ANN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

The protection of intellectual property rights in the US and other countries helps encourage ongoing research and development of innovative pharmaceutical and biotechnology treatments and advances the quality of healthcare for people. To the extent that public policies diminish such rights in the US or elsewhere, sanofi-aventis, the foreign parent company will be impacted negatively.

Registrant Name: SANOFI-AVENTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: VET (one per page)

16. Specific lobbying issues:

HR2642 "Military Construction and Veterans Affairs Appropriations Act of 2008" (issues/provisions related to the quality of healthcare delivered by the Veterans Health Administration)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

Veterans Affairs, Dept of (VA)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HODGE, RICHARD

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Health care quality issues related to Veterans' healthcare could negatively impact the sanofi-aventis US operation which could result in less than optimal pharmaceutical care for US veterans. To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S., so too sanofi-aventis, the parent company that is a foreign company, will likewise be impacted.

Signature: ON FILE Date: Aug 13, 2007

Printed Name and Title: JONATHAN B. SPEAR, ASSOCIATE VICE PRESIDENT, FEDER -

Registrant Name: SANOFI-AVENTIS Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 13, 2007

Printed Name and Title: -